SCHEMBL13638295

SCHEMBL13638295

C=C1CC(Nc2nccc(-c3ccc(C(=O)O)s3)n2)CC(C)(C)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 10/20 0.38
TEC P42680 1/20 0.37
TXK P42681 1/20 0.37
BTK Q06187 1/20 0.37
ITK Q08881 1/20 0.37
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
CDK4 P11802 5/20 0.36
CDK1 P06493 4/20 0.36
CCNB1 P14635 4/20 0.36
CCNA2 P20248 4/20 0.36
CCND1 P24385 4/20 0.36
CDK2 P24941 4/20 0.36
CCNA1 P78396 4/20 0.36
KDM4E B2RXH2 2/20 0.36
GLA P06280 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CCNE1 P24864 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14612850 0.91 AKT3 (0.37) AKT3TECTXKBTKITK
SCHEMBL13638669 0.89 CDK2 (0.36) AKT3TECTXKBTKITK
SCHEMBL13638569 0.87 AKT3 (0.37) AKT3TECTXKBTKITK
SCHEMBL13638474 0.86 AKT3 (0.50) AKT3TECTXKBTKITK
SCHEMBL3470259 0.86 AKT3 (0.42) AKT3TECTXKBTKITK
SCHEMBL13638466 0.85 AKT3 (0.62) AKT3TECTXKBTKITK
SCHEMBL13638460 0.84 AKT3 (0.35) AKT3TECTXKBTKITK
SCHEMBL14612785 0.84 IKBKB (0.37) AKT3ITKMAPK8MAPK9MAPK10
SCHEMBL13638454 0.84 CDK4 (0.36) MAPK8MAPK9MAPK10CDK4CDK1
SCHEMBL13638578 0.84 IKBKB (0.37) AKT3MAPK8MAPK9MAPK10CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed